Gilead, Johnson & Johnson, and 3 Other Big Biopharmaceutical Stocks That Are Finding Favor - Barron's
1. Gilead receives a Buy rating with a price target increase to $126. 2. BofA Securities identifies Gilead as a top performer in biopharma stocks. 3. The company's HIV drug Biktarvy expected to beat estimates consistently. 4. Gilead is launching two new medicines in the next two years. 5. Analyst sees a potential 10% upside in Gilead's share price.